Recombinant Human G1/S-Specific Cyclin-D1 (CCND1) Protein (His)

Name: Recombinant Human G1/S-Specific Cyclin-D1 (CCND1) Protein (His)
Brand: Beta LifeScience
SKU: BLC-04394P
Availability: InStock

Greater than 90% as determined by SDS-PAGE.

Based on the SEQUEST from database of E.coli host and target protein, the LC-MS/MS Analysis result of this product could indicate that this peptide derived from E.coli-expressed Homo sapiens (Human) CCND1.

Collections: High-quality recombinant proteins, Other recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human G1/S-Specific Cyclin-D1 (CCND1) Protein (His) is produced by our E.coli expression system. This is a full length protein.
Purity	Greater than 90% as determined by SDS-PAGE.
Uniprotkb	P24385
Target Symbol	CCND1
Synonyms	AI327039; B cell CLL/lymphoma 1; B cell leukemia 1; B cell lymphoma 1 protein; B-cell lymphoma 1 protein; BCL 1; BCL-1; BCL-1 oncogene; BCL1; BCL1 oncogene; ccnd1; CCND1/FSTL3 fusion gene; CCND1/FSTL3 fusion gene; included; CCND1/IGHG1 fusion gene; CCND1/IGHG1 fusion gene; included; CCND1/IGLC1 fusion gene; CCND1/IGLC1 fusion gene; included; CCND1/PTH fusion gene; CCND1/PTH fusion gene; included; CCND1_HUMAN; cD1; Cyl 1; D11S287E; G1/S specific cyclin D1; G1/S-specific cyclin-D1; Parathyroid adenomatosis 1; PRAD1; PRAD1 oncogene; U21B31
Species	Homo sapiens (Human)
Expression System	E.coli
Tag	N-6His
Target Protein Sequence	MEHQLLCCEVETIRRAYPDANLLNDRVLRAMLKAEETCAPSVSYFKCVQKEVLPSMRKIVATWMLEVCEEQKCEEEVFPLAMNYLDRFLSLEPVKKSRLQLLGATCMFVASKMKETIPLTAEKLCIYTDNSIRPEELLQMELLLVNKLKWNLAAMTPHDFIEHFLSKMPEAEENKQIIRKHAQTFVALCATDVKFISNPPSMVAAGSVVAAVQGLNLRSPNNFLSYYRLTRFLSRVIKCDPDCLRACQEQIEALLESSLRQAQQNMDPKAAEEEEEEEEEVDLACTPTDVRDVDI
Expression Range	1-295aa
Protein Length	Full Length
Mol. Weight	37.7kDa
Research Area	Cell Cycle
Form	Liquid or Lyophilized powder
Buffer	Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Storage	1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes	Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function	Regulatory component of the cyclin D1-CDK4 (DC) complex that phosphorylates and inhibits members of the retinoblastoma (RB) protein family including RB1 and regulates the cell-cycle during G(1)/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complex and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1) phase. Hypophosphorylates RB1 in early G(1) phase. Cyclin D-CDK4 complexes are major integrators of various mitogenenic and antimitogenic signals. Also substrate for SMAD3, phosphorylating SMAD3 in a cell-cycle-dependent manner and repressing its transcriptional activity. Component of the ternary complex, cyclin D1/CDK4/CDKN1B, required for nuclear translocation and activity of the cyclin D-CDK4 complex. Exhibits transcriptional corepressor activity with INSM1 on the NEUROD1 and INS promoters in a cell cycle-independent manner.
Subcellular Location	Nucleus. Cytoplasm. Nucleus membrane.
Protein Families	Cyclin family, Cyclin D subfamily
Database References	HGNC: 1582 OMIM: 168461 KEGG: hsa:595 STRING: 9606.ENSP00000227507 UniGene: PMID: 30226542 autophagic degradation machinery and cyclin D1 linked to hepatocellular carcinoma tumorigenesis PMID: 29328502 FOXD2-AS1 could promote the growth of chondrocytes by targeting miR-206/CCND1 axis. PMID: 30119190 CCND1 , C-MYC , and FGFR1 amplifications were observed in 34.28%, 28.57%, and 17.14% of the 35 samples (invasive ductal breast carcinoma). PMID: 30119151 High CCND1 expression is associated with lung adenocarcinoma. PMID: 30066899 Down-regulation of Apaf-1 protein and the overexpression of Cyclin D1 and AQP-5 proteins possibly contribute to an aggressive serous ovarian carcinoma with a high risk of recurrence and poor response to the first-line chemotherapy. PMID: 30072015 Results provide evidence that Cyclin D1 is a mediator for WDR5-induced proliferation and cell cycle change in gastric neoplasm. PMID: 29125890 CNV analysis disclosed that plasma CCND1/CDKN2A ratio is correlated with EBV DNA load in NPC patients' plasma and could serve as a screening test to select potential CDK4/6 inhibitor treatment candidates. Based on our NPC PDX model and RNA sequencing, Palbociclib, a cyclin-dependent kinase inhibitor, proved to have anti-tumor effects by inducing G1 arrest. PMID: 30236142 Cyclin D1b markedly amplified integrin alphavbeta3 expression, which was further up-regulated under lipopolysaccharide stimulation. PMID: 30074214 This meta-analysis suggested that CCND1 rs9344 polymorphism might be associated with the risk of HCC among Caucasians. PMID: 29970717 Results show that CCND1 expression is regulated by LET7A which directly targets its 3'UTR in A549 lung cancer cells. PMID: 30201337 Authors found that the phenotypic alterations by miR-365 were partially due to downregulation of CCND1 and BCL2 oncogenes. PMID: 29858490 USP22 and CCND1 levels correlate in patient lung and colorectal cancer samples and our preclinical studies indicate that targeting USP22 in combination with CDK inhibitors may offer an approach for treating cancer patients whose tumors exhibit elevated CCND1. PMID: 30224477 miR449a5p may control squamous cell carcinoma proliferation through the negative regulation of cyclin D1 expression. PMID: 29845226 Findings demonstrated that Cyclin D1 is overexpressed in hepatocellular carcinoma cells (HCC) and that its silencing can suppress cell proliferation and promote cell apoptosis of HCC. PMID: 28885717 uc.338 could promote proliferation and cell cycle G1/S transition, and might target p21 downregulation and cyclin D1 upregulation. PMID: 29901203 overexpressed PKM2 led to increased CCND1 and decreased CDKN1A expression, whereas underexpressed PKM2 led to decreased CCND1 and increased CDKN1A expression in ovarian cancer cells. PMID: 29752805 CCND1 G870A polymorphism may increase the risk of lung cancer in smokers from North India, and it may be associated with the overall survival of small-cell lung cancer patients PMID: 30086699 these results define a tumor-supportive role for CDCA3. PMID: 29627567 High CCND1 expression is associated with breast cancer. PMID: 29047106 The novel EGR1-CCND1 axis contributes to the G1 phase arrest and cell proliferation in glioma PMID: 29246166 the focal adhesion component paxillin is a cytoplasmic substrate of Ccnd1.Cdk4. PMID: 27181366 in oral tumor cells, overexpression of cyclin D1 occurs through the activation of STAT3 and the deregulation of degradation pathway of cyclin D1 which may favors maintaining its accumulated level in cells. It also demonstrated that cyclin D1 expression can be controlled by targeting the STAT3 with its siRNA. PMID: 29516928 more than 50 cyclin D1-positive cells per high-power field were detected within the proliferation centres PMID: 29254788 Downregulation of miR-138 increases the gene and protein expression of its potential target CCND1 in OLP mucosa which might have a pivotal role in the disease pathogenesis. PMID: 28275859 A possible contribution of cyclin D1 and hnRNP-K expression in the initiation and progression of urinary bladder carcinoma. PMID: 29480994 Un-methyaltion at -56 and -54 bp CpG in the CCND1 promoter serves as a predictor for invasive progression in arsenic-induced Bowen's disease patients. PMID: 29103775 PSAT1, which is overexpressed in ER-negative breast cancers, is activated by ATF4 and promotes cell cycle progression via regulation of the GSK3beta/beta-catenin/cyclin D1 pathway. PMID: 29216929 Positivity of p53 and cyclin D1 was not found to be predictive of survival in patients with esophageal SCC which might be due to the small sample size of the present survey. PMID: 27975182 Studied effects of Taxillus yadoriki and Neolitsea sericea extracts on cell proliferation of cancer cells through cyclin D1 proteasomal degradation. PMID: 29925351 Findings indicate the substrate specificity of the F-box protein FBXO31 and the mechanism of FBXO31-regulated cyclin D1 protein turnover. PMID: 29279382 The authors report a previously unknown long noncoding RNA which, together with CNBP, is involved in the fine-tuned regulation of CCND1 mRNA stability, without which CCND1 exhibits, at most, partial expression. PMID: 29199958 According to immunohistochemistry and immunoblot analysis, the expression levels of cyclin D1, cyclin E, pRb, and Ki67 in psoriasis lesions decreased after treatment and were similar with those in the normal group PMID: 29115643 Further study revealed AP000439.3 can regulate expression of CCND1 through enhancing estrogen receptor induction of CCND1. This finding revealed lncRNAs may serve as important effectors of ER in regulation of gene expression and cell phenotype in breast cancer PMID: 29048636 miR-720 acted as a tumour suppressor in pancreatic cancer by directly targeting CCND1. PMID: 28990111 Results identified NKX2-1-binding motifs in the cyclin D1 promoter and indicate that NKX2-1 directly and positively regulates transcription of cyclin D1 in lung adenocarcinoma. PMID: 28634225 Results suggest that dysregulation and activation of the cell cycle proteins CDK4/CDK6-CCND1-phospho-RB1 axis is associated with higher proliferative index in neuroendocrine tumors (NETs). PMID: 28991877 Results indicated that miR-193a-3p suppressed gastric growth and motility, at least partly, by directly targeting cyclin D1 (CCND1) and ETS proto-oncogene 1 (ETS1) expression. PMID: 29848678 Greater frequency of cyclin D1 expression was revealed in normal endometrial tissues in comparison with carcinomas. The distribution pattern of cyclin D1 immunoexpression suggests poor prognoses in endometrial carcinoma patients. PMID: 28965628 High Expression of CCND1 is associated with liver cancer. PMID: 28415588 Impact of 9p deletion and p16, Cyclin D1, and Myc hyperexpression on the outcome of anaplastic oligodendrogliomas. PMID: 29489901 These findings indicate that miRNA494 and its target cyclin D1 may be a crucial axis for Nerve growth factor in regulating the proliferation of human corneal epithelial cell. PMID: 28765880 INSR rs1051690 SNP is associated with increased risk of gastric cancer, while polymorphisms in IL12B, CCND1 and IL10 genes are not linked with the presence of gastric cancer PMID: 28596683 Authors showed that CCND1 is a direct target of miR-93, and the dysregulation of the miR-93/CCND1 signaling pathway is responsible for the development of ventricular remodeling. PMID: 28817550 PD-L1 protein abundance is regulated by cyclin D-CDK4 and the cullin 3-SPOP E3 ligase via proteasome-mediated degradation PMID: 29160310 We conclude that EMSY and CCND1 work in collaboration and contribute to the pathogenesis of lung cancer. PMID: 28824300 Transfection of cells with ClC-3 siRNA decreased the expression of cyclin D1, cyclin dependent kinase 4 and 6, and increased the expression of cyclin dependent kinase inhibitors (CDKIs), p21 and p27. Pretreatments of cells with p21 and p27 siRNAs depleted the inhibitory effects of ClC-3 siRNA on the expression of CDK4 and CDK6, but not on that of cyclin D1 PMID: 27451945 HPV infection was significantly associated with amplification of both EGFR (76.5%) and cyclin D1 (73.0%). PMID: 28741068 our data demonstrated for the first time that inhibition of RAD51 suppressed the cervical cancer cell proliferation and the growth of cervical cancer xenografts by attenuating cell cycle transition, which could be a functional link between RAD51 and cyclin D1 and p21 PMID: 28627709 REVIEW: addresses the implication of SOX11 overexpression and frequent genetic lesions, cooperating with cyclin D1 underlying the pathogenesis of mantle cell lymphoma PMID: 28466437

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.